Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

2,101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One-Year Outcomes after PCI Strategies in Cardiogenic Shock.
Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, Eitel I, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Jobs A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Hunziker L, Savonitto S, Torremante P, Vrints C, Schneider S, Zeymer U, Desch S; CULPRIT-SHOCK Investigators. Thiele H, et al. Among authors: huber k. N Engl J Med. 2018 Nov 1;379(18):1699-1710. doi: 10.1056/NEJMoa1808788. Epub 2018 Aug 25. N Engl J Med. 2018. PMID: 30145971 Free article. Clinical Trial.
Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.
De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW. De Luca G, et al. Among authors: huber k. Atherosclerosis. 2009 Nov;207(1):181-5. doi: 10.1016/j.atherosclerosis.2009.03.042. Epub 2009 Apr 5. Atherosclerosis. 2009. PMID: 19426981
Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors.
De Luca G, Gibson CM, Huber K, Zeymer U, Dudek D, Cutlip D, Bellandi F, Noc M, Emre A, Zorman S, Gabriel HM, Maioli M, Rakowski T, Gyöngyösi M, Van't Hof AW; EGYPT Cooperation. De Luca G, et al. Among authors: huber k. Am Heart J. 2009 Sep;158(3):416-21. doi: 10.1016/j.ahj.2009.06.029. Am Heart J. 2009. PMID: 19699865
The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention.
Ross AM, Huber K, Zeymer U, Armstrong PW, Granger CB, Goldstein P, Bogaerts K, Van de Werf F. Ross AM, et al. Among authors: huber k. JACC Cardiovasc Interv. 2009 Oct;2(10):925-30. doi: 10.1016/j.jcin.2009.08.009. JACC Cardiovasc Interv. 2009. PMID: 19850250 Free article.
Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.
Jarai R, Huber K, Bogaerts K, Droogne W, Ezekowitz J, Granger CB, Sinnaeve PR, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT IV-PCI investigators. Jarai R, et al. Among authors: huber k. Am Heart J. 2010 Jan;159(1):131-40. doi: 10.1016/j.ahj.2009.11.001. Am Heart J. 2010. PMID: 20102879 Clinical Trial.
Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial.
Jarai R, Huber K, Bogaerts K, Sinnaeve PR, Ezekowitz J, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI investigators. Jarai R, et al. Among authors: huber k. Crit Care Med. 2010 Sep;38(9):1793-801. doi: 10.1097/CCM.0b013e3181eaaf2a. Crit Care Med. 2010. PMID: 20562693 Clinical Trial.
2,101 results